Open Label Use Of RiaStap During Aortic Reconstruction
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this study is to administer fibrinogen concentrate (RiaSTAP, CSL
Behring, Marburg, Germany) with the goal of treating coagulopathic bleeding by improving
hemostasis thereby reducing overall blood product transfusion after separation from
cardiopulmonary bypass following aortic reconstructive surgery. With the current sample size
this is a pilot study and in effect will determine the fibrinogen level response to
fibrinogen concentrate administered during aortic reconstructive surgery. It will be
underpowered to detect reduction in bleeding but comparison to historical controls will be
included as a secondary outcome.